Partial deletion of the long arm of chromosome 7 (7q−) is a frequent chromosomal aberration in many neoplasias, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Recurrent deletions, leading to loss of heterozygosity (LOH), may be indicative of a tumor suppressor gene nearby. We studied eight AML or MDS patients with 7q−, in order to define the commonly deleted area in more detail. Separated blood lymphocytes and granulocytes were typed with 48 polymorphic microsatellite markers, and the heterozygosity between the two cell lineages was compared. The minimum commonly deleted region spanned from D7S658 to D7S655. Unexpectedly, four of the patients showed remarkable homozygosity in both lymphocytes and granulocytes around the commonly deleted area, and thus no deletions could be demonstrated by comparing the two cell lineages. Comparison to leukemic patients without 7q− and to normal individuals revealed that the homozygosity was restricted to patients with 7q−. We suggest that a specific mechanism, such as mitotic recombination in bone marrow stem cells, leading to homozygosity in both granulocytes and lymphocytes, represents a leukemogenetic step in these patients.
Introduction
Neoplastic hematologic cells often contain numerical or structural cytogenetic abnormalities that occur either alone or together. 1, 2 In acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), the most common solely occurring aberrations include monosomy 7 (−7) and the deletion of the long arm of chromosome 7 (7q−). 3 Both terminal and interstitial deletions as well as inversions and translocations of 7q have been described, and the breakpoints vary among the patients. [4] [5] [6] [7] [8] The most commonly deleted segment is 7q22-q36, where two distinct critical regions have been postulated; 7q22 and 7q32-q34. 3, [6] [7] [8] [9] [10] Aberrations with 7q− or −7 are present in up to 5% of all AML or MDS cases, and their frequency is even higher in therapy-related AML or MDS. 4, 5, 9 Clinically, monosomy 7 and 7q− are associated with a relatively poor response to chemotherapy and short survival, 11 and cytogenetic studies have suggested the presence of a gene(s) that is responsible for the poor prognosis in 7q31 or 7q32. 12, 13 Deletions of 7q are also common in many solid tumors, including breast tumors, prostate carcinomas and colon carcinomas, where loss of heterozygosity (LOH) at the band 7q31 is a frequent finding. [14] [15] [16] [17] In these tumors, LOH is sometimes associated with poor survival. 14 In solid tumors, it is possible to study LOH by comparing the heterozygosity of DNAs extracted from the tumor and normal tissue, 18 many cases, the deletions have been characterized. 16, 17, 19 In AML or MDS, the granulocyte-monocyte lineage contains affected cells, and LOH can thus be studied by comparing the heterozygosity between DNAs extracted from granulocytes and lymphocytes. [20] [21] [22] [23] The biological significance of the acquired partial loss of the long arm of chromosome 7 remains unknown. One or more tumor suppressor genes have been suspected residing there, but definitive evidence for such genes is lacking. 3, [6] [7] [8] 17, 19, 21 The high resolution linkage maps that have recently become available and provide densely spaced, highly polymorphic microsatellite markers, 24 permit a much more accurate analysis of these molecular changes. This study was designed to test the use of PCR amplification of the highly polymorphic microsatellite markers in identifying deletions of 7q in AML and MDS patients, and to characterize the deletions in more detail. Surprisingly, we observed that in some of these patients, both lymphocytes and granulocytes are highly significantly more often homozygous for chromosome 7 long arm markers than was expected. To determine whether this phenomenon was restricted to bone marrowderived cells we typed two patients' mesenchymal organ DNA with markers that were homozygous in their lymphocytes and granulocytes.
In addition to 7q− patients, 28 AML patients with no visible aberrations of chromosome 7 were studied to ascertain possible LOH or exceptional homozygosity. No LOH was found, and the heterozygosity of this population was also close to that of the normal population. We interpret these findings to suggest two consecutive or alternative molecular steps in the pathogenesis of myeloid disorders involving chromosome 7 abnormalities.
Materials and methods
Patients and specimens with 7q− Eight patients with the clinical diagnosis of AML or MDS, whose chromosome analysis had revealed deletion of the long arm of chromosome 7 exclusively or among other aberrations, were selected for this study. Cytogenetic studies of unstimulated bone marrow and phytohemagglutinin-stimulated blood cells were performed as described elsewhere. 25 The clinical and original cytogenetic findings of the patients are summarized in Table 1 .
Red blood cells were removed by precipitation with 0.6% dextran from heparinized blood samples. Mononuclear cells and granulocytes were separated from the remaining white blood cell rich plasma by Ficoll gradient centrifugation. Purity of the fractions has been consistently better than 80%. DNA was extracted from lymphocyte and granulocyte cell fractions separately using a standard proteinase K digestion, phenol extraction and ethanol precipitation method. The granulocytes of patients 1 and 4 were studied by the comparative genomic hybridization (CGH) method, described elsewhere, 28 in order to exclude any changes between deleted chromosome 7 material and other chromosomes.
Tissue specimens taken during operation or autopsy were obtained from patients 4 (gall bladder) and 6 (liver). The samples had been fixed in buffered formaldehyde and embedded in paraffin. DNA was extracted from tissue slices as described. 29 AML patients with no abnormalities of chromosome 7
In addition to patients with 7q−, 28 patients with AML and no cytogenetic abnormalities of chromosome 7 were studied. Four of them had other than chromosome 7 abnormalities and 24 had normal karyotypes in the cytogenetic analysis. DNA samples from both blood cells and bone marrow cells were obtained from 17 patients, blood cells alone from 10 patients, and bone marrow cells alone from one patient.
Non-leukemic controls
The population frequency of heterozygosity for chromosome 7 markers was estimated from samples used to map recessive disease genes in the laboratories of Department of Medical Genetics, University of Helsinki. To avoid bias in allele frequencies, families segregating a disease gene located in chromosome 7 were excluded. Heterozygosity in unrelated individuals (n = 14 to 381 for different markers) was determined for 19 polymorphic markers located in chromosome 7.
Markers and PCR analyses
Altogether 48 polymorphic microsatellite markers for chromosome 7 were used in the analysis of patients with 7q−. The markers are listed in Table 2 . Granulocyte-and lymphocytederived DNAs were amplified separately by PCR in 10-20 l reactions that were slightly varied to optimize for each marker. Typical conditions consisted of 30-35 cycles of 94°C, 55°C and 72°C each for 30-45 s. Template DNA was varied between 5-100 ng to check for consistency of interpretation. After PCR amplification, the samples were electrophoresed in 6% polyacrylamide-7M urea sequencing gels. Films were exposed from 20 min to 4 days. Alleles present in the two cell fractions were compared for each patient. Gall bladder and liver DNA from patients 4 and 6, respectively, were typed with markers D7S486 and D7S514.
Fluorescent markers D7S531, D7S507, D7S493, D7S519, D7S515, D7S486, and D7S636, part of the ABI PRISM Linkage Mapping Set, panel 12 (Applied Biosystems Division of Perkin Elmer (PE/ABI), Foster City, CA, USA), were used for microsatellite analyses of AML patients without chromosome 7 aberrations. The PCR assays were performed according to the manufacturer's instructions in the ABI Catalyst 800 Labstation, and analyzed together with Tamra-500 as an internal size standard on a 373 Stretch DNA Sequencer using GeneScan software (PE/ABI). Allele sizing was performed with the Genotyper 1.1 program. The degree of heterozygosity was determined for each marker. In cases where both bone marrow and blood cell DNA was available, the heterozygosity of the two samples was compared.
Results

Comparative genomic hybridization
Deletion of the long arm of chromosome 7 was confirmed for patients 1 and 4 (data not shown). Hence, no evidence of translocation of the deleted chromosome 7 material to other chromosomes was detected in these patients.
Granulocytes show loss of alleles in patients with 7q− All patients were heterozygous for several markers on chromosome 7 as demonstrated by the presence of two different allelic bands in the lymphocyte-derived DNA. The presence of two equally strong allelic bands also indicated that all lymphocyte fractions consisted mostly of disomic cells. LOH, indicative of a deletion, was found to be present when one of the two allelic bands observed in lymphocyte DNA was absent or disproportionately weak in granulocyte-derived DNA (Figure 1 ).
Consistency of results
At the beginning of this study, it was considered that the visual strength of allelic bands might affect the interpretation of LOH. Variation in the strength of alleles might result from inconsistent amounts of template DNA in PCR assays or the unequal amplification in different reaction tubes. Two precautions were taken to exclude a bias resulting from such variation. First, each result was scored independently by two investigators. Second, the effect of varying DNA concentrations was studied directly. The scoring of results was identical in about 90% of cases of successful amplification. In cases of differing interpretation, the experiment was repeated at least twice and scored again, and in case of doubt the result was scored as missing. Unsuccessful amplifications in most of the failed cases were overcome by repeating the PCR assay, and missing results were left PCR analysis of patients 1 to 4 with markers D7S527 and D7S477. Lymphocyte-derived DNA (LY) from patients 1 and 3 show two alleles with both markers, whereas only one allelic band is observed with these patients' granulocyte-derived DNA (GR), indicating LOH. The missing or weaker bands are marked by arrows. For patients 2 and 4, two allelic bands are seen in the lymphocyte lane as well as granulocyte lane with both markers, demonstrating an informative situation without LOH. out of analyses. Overall, 47/384 (12%) of assays were scored missing ( Table 2 ) and they do not affect overall interpretations. As shown in Figure 2 , the concentration of template DNA and resulting variation in the strength of allelic bands had little or no effect on the interpretation of results.
Range of breakpoints in 7q
LOH was detected in granulocyte-derived DNA of patients 1, 2, 3 and 8 with six to 18 informative markers on 7q. The most proximal informative markers that were found to be deleted were D7S660 for patients 1 and 3; D7S658 for patient 2; and D7S515 for patient 8. These markers have been mapped to 7q21-q31, and span a genetic distance of approximately 26 cm. The distal breakpoints of the deletions of patients 1, 2 and 3 were delineated by markers D7S655, D7S635, and D7S631, respectively, which were the most distal deleted informative markers; in patient 8 the distal breakpoint remained ambiguous ( Table 2 ). The common deleted segment between markers D7S658 and D7S655 is located in 7q31 and span a genetic distance of 12 cm.
High degree of homozygosity in some of the patients with 7q− In patients 4, 5, 6 and 7, an unexpectedly high rate of homozygosity in both lymphocytes and granulocytes was detected with the tested markers. This made impossible the localization of these patients' deletions by comparing the heterozygosity of the two cell lineages. With these four patients, altogether 159 independent determinations for 48 chromosome 7 markers were successful; homozygosity in both cell fractions was observed in 86 (54%) determinations. The difference between the observed degrees of heterozygosity and the expected values determined for each marker previously 24 is highly significant (1.1 × 10 −6 ; t-test, two-tailed). To assess whether the degree of homozygosity in these 7q− patients was the same all over chromosome 7q, the values were normalized for each marker by dividing the observed heterozygosity in the patient group by the expected heterozygosity ( Table 2 ). The results are displayed graphically in Figure 3 , where a sliding average over five adjacent markers was applied to diminish random fluctuation between neighboring markers. This analysis showed that the region of low heterozygosity roughly coincides with the commonly deleted region.
To exclude the possibility that homozygosity was generally more common in the Finnish population, data were also compiled from previous typing results of unrelated Finnish individuals. For the marker D7S496, 278 individuals out of 381 typed were heterozygous (73%), which is very close to the published value (74%). Between 14 and 33 individuals had been typed for 18 other chromosome 7 markers. In these typings, 545 assays out of 716 performed were heterozygous (76%). This figure is again very close to the average heterozygosity (79%) expected for these markers.
Patients may be constitutionally heterozygous
Gall bladder DNA from patient 4, whose lymphocyte and granulocyte DNAs were homozygous for markers D7S486 and D7S514, was heterozygous for both markers, indicating consitutional heterozygosity (Figure 4) . The liver DNA from patient Varying degree of heterozygosity along chromosome 7q. Heterozygosity value for each marker was normalized by dividing the observed heterozygosity value by the expected heterozygosity published previously for each marker. 24 Each column represents the sliding average over five adjacent markers. The region of low heterozygosity roughly coincides with the deleted region at 7q.
5 did not amplify and this patient's constitutional zygosity remained uncertain.
Patients with no cytogenetic abnormalities in chromosome 7
To study whether LOH or homozygosity in 7q occurs frequently in leukemic patients without visible chromosome 7 abnormalities, a group of 28 AML patients were genotyped for seven chromosome 7 markers. Altogether 171 independent genotypings were performed with markers D7S531, D7S507, D7S493, D7S519, D7S515, D7S486 and D7S636. Of the 17 patients from whom both bone marrow and blood DNA was available, no one showed LOH when comparing the two samples of each patient. Heterozygosity was observed in 135 determinations (79%), differing much less from the average expected heterozygosity value for these markers (84%) than the heterozygosity of the four 7q− patients (46% observed vs 74% expected).
Discussion
This study was designed to test the use of microsatellite markers in defining the extent of chromosome 7 deletions in patients with AML or MDS. In the course of the study, we unexpectedly found that homozygosity was common in a subgroup of patients. We attempted to delineate the phenomenon by studying other leukemic patients and other tissues from those affected from whom material was available.
All patients with 7q− were found to be heterozygous with a similar intensity of alleles in both cell fractions for at least four distinct markers. This result shows that all patients possessed two different copies of chromosome 7. In all cases, a loss or disproportionate weakening of one allelic band in the granulocyte DNA as compared to lymphocyte DNA was used to define a marker as deleted. The results indicated that the chromosome 7 breakpoints were different in different patients and that a common deleted segment was delineated by the markers D7S658 and D7S655, spanning a genetic distance of 12 cm in 7q31. At least three of the deletions were interstitial. The deletion of patient 3 was cytogenetically interpreted as terminal, yet the molecular analysis revealed a submicroscopic terminal segment, supporting previous findings. 30, 31 CGH, applied to exclude any translocations between chromosome 7 and other chromosomes in patients 1 and 4, confirmed the cytogenetic interpretation of a deletion of 7q, and no transfer of chromosome 7 material elsewhere.
In four patients, a remarkably high rate of homozygosity in both lymphocyte and granulocyte fractions made the delineation of the deletions difficult; since there was no heterozygosity, no LOH could be observed. The degree of heterozygosity in these patients was found highly significantly lower than expected. All of these patients, however, showed heterozygosity for markers in the proximal 7q, showing that the finding was not merely an artifact arising from complete loss of one chromosome 7. The degree of heterozygosity in these four 7q− patients varied by the position of the markers along the chromosome. The lowest heterozygosity values coincided roughly with the segment that was deleted in the other four patients (Figure 3) . In individual patients, homozygous segments tended to be continuous over lengthy segments (Table 2) .
This finding is unlikely to result from an overall difference in the heterozygosity in the Finnish population. For comparison, we collected results from our laboratory for several markers for chromosome 7 used in previous studies, and found heterozygosity values very close to those published. Furthermore, the genotyping of 28 unselected leukemic patients without chromosome 7 abnormalities revealed a heterozygosity value that was close to the expected figure. No LOH among these patients was found either, supporting the findings that LOH at 7q is rare in AML or MDS patients without cytogenetically detectable deletions. 10, 30 That the heterozygosity was slightly lower than expected in unselected leukemic patients may deserve further attention.
We interpret these findings to suggest that the homozygosity in four of the 7q− patients was caused by a specific molecular mechanism, such as mitotic recombination in a bone marrow stem cell that led to the duplication of specific chromosomal segments in both homologous chromosomes and thus homozygosity in both lymphocyte and granulocyte DNA. To study Typing of lymphocyte, granulocyte and gall bladder DNA from patient 4 with markers D7S486 and D7S514. One allelic band in the lymphocyte (LY) and granulocyte (GR) lanes and two bands in the gall bladder tissue lane (T) with both markers indicate constitutional heterozygosity in this patient.
this possibility further, we genotyped mesenchymal tissues from two patients. Typing of a tissue sample from gall bladder of one patient suggested that she indeed was constitutionally heterozygous for two markers found homozygous in the lymphocytes and granulocytes.
Neuman et al 10 discussed the possibility of mitotic recombination in conjunction with LOH from chromosomes 5 and 7. Even though the authors did not report increased homozygosity, it appears from their data that many patients were left out of analysis because of uninformativeness. Recently, Lewis et al 32 studied five 7q− patients with clonal myeloid disorders with restriction fragment length polymorphisms for nine chromosome 7q genes. Of the 45 analyses, only 12 were found to be heterozygous (27%). Although the material is too small for statistical analysis, this result is in line with our results.
In earlier studies 10, 21, 32 an increased level of homozygosity was easily missed because of the low heterozygosity of the RFLP markers that were used. In addition, fluorescence in situ hybridization (FISH) analysis, a method used in several recent studies concerning 7q aberrations in myeloid disorders, [6] [7] [8] cannot detect LOH arising from mitotic recombination. Our study presented here is the first where tens of highly polymorphic markers have been used, allowing a statistical comparison rather than dismissing homozygosity as 'bad luck', or missing LOH because of two identical FISH signals.
Our results suggest that two distinct molecular mechanisms affecting chromosome 7 may be involved in the pathogenesis of myeloid disorders. The first, earlier event may have rendered a bone marrow stem cell homozygous for a critical segment of chromosome 7. This event leads to homozygosity of both the lymphoid and myeloid lineages of the bone marrow. In the second, later event, a bone marrow clone lost part of the chromosome by deletion. The deletion is confined to the myeloid lineage and does not affect lymphocytes.
Why would there be two consecutive steps (reduction to homozygosity and deletion) in the leukemic process involving 7q? There are many possible alternatives that current data cannot distinguish. One alternative is that more than one gene would be involved as suggested earlier; [6] [7] [8] [10] [11] [12] [13] this alternative is in line with a multistep process of carcinogenesis and somatic recombination as a carcinogenic event. [33] [34] [35] [36] Two distinct critical segments in 7q might be involved in the two events. Homozygosity would here cause inactivation of a tumor-suppressor gene by introducing two copies of a mutated or inactivated gene. An additional event (deletion) would then trigger the cell for transformation either by disrupting or inactivating another gene. Alternatively, the two steps might involve a single gene and its dosage alterations, at first by resulting in a pair of homozygous chromosomal segments and diminished level of protein, and then by deleting one homologous segment, leading to insufficient protein.
The nature and role of the gene(s) that are critically involved in these hypothetical events are not known. The commonly deleted and excessively homozygous segment of the long arm of chromosome 7 can be considered a candidate region harboring such genes. The study of heterozygosity may provide a novel marker in attempts to map the gene(s) more precisely.
